enGene Therapeutics Inc (ENGN) vs Seer, Inc. (SEER)

enGene Therapeutics Inc and Seer, Inc. are both Biotechnology companies. enGene Therapeutics Inc and Seer, Inc. are of similar size ($114.6M and $113.0M). enGene Therapeutics Inc has the higher net margin (0.00% vs −478.1%) and the higher return on invested capital (0.00% vs −60.8%). Across the 14 metrics below, Seer, Inc. leads on 9 and enGene Therapeutics Inc on 5.

Valuation

Metric ENGN SEER Biotechnology median
P/E n/m n/m 8.50
P/S n/m 7.88 9.71
P/B 0.51 0.50 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.91 0.64 0.64
EV/Sales n/m (2.87) 9.21
Earnings yield (123.72%) (60.10%) (33.15%)
Free cash flow yield (89.30%) (39.27%) (25.50%)

Profitability

Metric ENGN SEER Biotechnology median
Gross margin — 47.70% 65.16%
Operating margin 0.00% (498.19%) 0.00%
Net margin 0.00% (478.05%) 0.00%
Free cash flow margin 0.00% (309.34%) 0.00%
Return on equity (60.50%) (26.45%) (56.36%)
Return on assets (48.84%) (23.47%) (48.04%)
Return on invested capital 0.00% (60.78%) 0.00%

Growth

Metric ENGN SEER Biotechnology median
Revenue growth (TTM) — (12.71%) 6.02%
EPS growth (last fiscal year) (56.85%) 7.91% 30.26%
Revenue growth, 5-year CAGR — 90.78% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENGN SEER Biotechnology median
Debt to equity 0.11 0.00 0.00
Current ratio 10.21 14.74 4.72
Net debt to EBITDA 1.42 2.63 0.96

Dividend

Metric ENGN SEER Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ENGN SEER Biotechnology median
Market cap 114.60m 112.96m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack